Physician profile
Colleen E Parent
NPI 1821293598
$2,414.32
in general payments reported to CMS, 2019-2025
27 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.01 · 2020: $283 · 2021: $975 · 2022: $478 · 2023: $223 · 2024: $209 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.01 | 2021-2025 | |
| Gilead Sciences, INC. | $297.18 | 2022-2025 | Yeztugo |
| Abbott Laboratories | $158.05 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Alkermes, INC. | $143.71 | 2022-2024 | Vivitrol |
| Indivior INC. | $133.48 | 2022-2024 | Sublocade |
| Novo Nordisk INC | $130.33 | 2020-2022 | |
| Orexo US, INC. | $98.72 | 2022-2024 | Zubsolv |
| Glaxosmithkline, LLC. | $88.35 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.67 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $49.95 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $47.97 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.72 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.67 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $36.85 | 2019-2024 | Farxiga |
| Neurocrine Biosciences, INC. | $35.90 | 2022-2024 | Ingrezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $33.59 | 2020 | |
| Lilly USA, LLC | $28.18 | 2021 | |
| Dermira, INC. | $24.21 | 2020 | |
| Pfizer INC. | $22.14 | 2021 | |
| Eisai INC. | $19.34 | 2021 | |
| Esperion Therapeutics, INC. | $19.21 | 2020 | |
| Allergan, INC. | $18.33 | 2020 | |
| Ibsa Pharma INC. | $15.82 | 2021 | |
| Amgen INC. | $15.71 | 2022 | |
| Astellas Pharma US INC | $14.61 | 2021 | |
| Sanofi Pasteur INC. | $14.29 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Parent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.